Corona Remedies IPO: Check IPO Date, Live Subscription and Key Details
Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto, pain management, and urology. The company is recognized as the second-fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) by domestic sales. It operates two manufacturing facilities in Gujarat and Himachal Pradesh and leverages a pan-India marketing network of 2,671 medical representatives.
Price Range
₹1008.0 - ₹1062.0
Issue Size
₹655.37 Cr
Lot Size
14 shares
IPO Type
Mainboard
GMP
₹342(+32.20%)
Est. Listing Price
₹1,404
Estimate Profit
₹4,788
Retail Portion
35%
Key Metrics
Check Live GMPGMPFace Value
₹10
EPS
30.21
P/E Ratio
35.15
RoNW
24.65%
ROE
27.5%
Debt to Equity
0.1
Advertisement
Timeline
IPO Opens
8 Dec
IPO Closes
10 Dec
Allotment
11 Dec
Listing
15 Dec
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 8 December 2025 | Subscription starts |
| IPO Close Date | 10 December 2025 | Subscription ends |
| Allotment Date | 11 December 2025 | Allotment |
| Listing Date | 15 December 2025 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,868 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,93,284 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,08,152 |
SHNI (Max)Below ₹10,00,000 | 67 | ₹9,96,156 |
BHNIAbove ₹10,00,000 | 68 | ₹10,11,024 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 50% |
| NII (Non-Institutional Investor) | 15% |
| Retail | 35% |
| Total | 100.00% |
IPO Objectives
- The IPO is entirely an Offer for Sale (OFS). The company will not receive any proceeds. All funds raised (₹655.37 Cr) will go to the selling shareholders (promoters and marquee investors).
Strengths
- The company has a Strong Growth Trajectory, being the second fastest-growing company among the top 30 IPM players by domestic sales (16.77% CAGR).
- It shows High Profitability & Capital Efficiency, reporting exceptional ROCE of 41.32% and ROE of 27.50% (FY25), and a strong EBITDA margin of 20.55%.
- The Chronic Therapy Focus (women’s health, cardio-diabeto) provides stable, recurring revenue similar to a subscription model.
- The business maintains a Clean Balance Sheet with minimal financial leverage and a low Debt/Equity ratio of 0.10 (FY25).
- It has a Pan-India Sales Network with 2,671 medical representatives, ensuring deep market penetration.
Weaknesses
- The IPO is a Pure Offer for Sale (OFS), meaning the company will not receive any proceeds to fund future growth or balance sheet improvements directly.
- The High Valuation with a P/E ratio of 35.15x (Post-IPO) is priced at a premium compared to many broad-spectrum peers.
- Therapeutic Concentration (over 65% of revenue from three main areas) increases vulnerability to competition or regulatory changes in those specific categories.
- The Regulatory Risk stems from branded generics in India being subject to government-imposed price caps (NLEM), which could impact margins.
- Supplier Dependency is high, as the company relies entirely on third-party suppliers for raw materials, posing supply chain and cost risks.
Advertisement
Financial Performance
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Revenue (₹ Cr.) | 348.56 | 1,202.35 | 1,020.93 | 891.1 |
| PAT (₹ Cr.) | 46.2 | 149.43 | 90.5 | 84.93 |
| Net Worth (₹ Cr.) | 607.02 | 606.34 | 480.41 | 408.52 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Corona Remidies | 10.71 | 35.15 | 27.5% | 607.02 |
| Abbott India Ltd. | 15.3 | 40.66 | 37.62% | 4,233 |
| Alkem Laboratories | 5.1 | 28.22 | 17.69% | 12,434 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0x | 1.76x | 293.8x |
| NII | 0.84x | 28.37x | 220.18x |
| S-HNI | 1.45x | 27.07x | 167.2x |
| B-HNI | 0.53x | 29.02x | 246.67x |
| RII | 0.96x | 6.9x | 30.39x |
| EMP | 1.48x | 4.37x | 15.56x |
| Total | 0.67x | 9.96x | 144.54x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 12,21,729 | 35,89,39,448 | 38,119.37 |
| NII | 9,16,960 | 20,18,97,066 | 21,441.47 |
| Small NII | 3,05,653 | 5,11,03,710 | 5,427.21 |
| Big NII | 6,11,307 | 15,07,93,356 | 16,014.25 |
| RII | 21,39,573 | 6,50,16,322 | 6,904.73 |
| EMP | 58,036 | 9,02,790 | 95.88 |
| Total | 43,36,298 | 62,67,55,626 | 66,561.45 |
Advertisement
Company Details
- Corona Remedies Ltd.
- CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat-380059
- +91 79 4023 3000
- complianceofficer@coronaremedies.com
- https://www.coronaremedies.com/
Registrar Details
- Bigshare Services Pvt.Ltd.
- +91-22-6263 8200
- ipo@bigshareonline.com
- https://ipo.bigshareonline.com/IPO_Status.html
Frequently Asked Questions
What is the core therapeutic focus of Corona Remedies?
Corona Remedies focuses on high-margin branded formulations in chronic therapies, primarily women’s healthcare, cardio-diabeto, pain management, and urology.
When will the Corona Remedies IPO open and close for subscription?
The Corona Remedies IPO is currently open for subscription from December 8, 2025, and will close on December 10, 2025.
What is the IPO price band and listing date?
The price band is set at ₹1008.00 to ₹1062.00 per share, and the tentative listing date on the BSE and NSE is December 15, 2025.
Is the Corona Remedies IPO a Fresh Issue or Offer for Sale (OFS)?
The issue is entirely an Offer for Sale (OFS) of ₹655.37 Cr. This means the company will not receive any proceeds; all funds will go to the selling shareholders.
What are the key financial strengths and valuation metrics of Corona Remedies?
The company is valued at a Post-IPO P/E of 35.15x (based on H1 FY26 annualized EPS). Key strengths include an excellent ROCE of 41.32%, PAT margin of 12.49%, and a low Debt/Equity ratio of 0.10.
Does Corona Remedies offer a discount to employees?
Yes, eligible employees bidding in the reserved category are being offered a discount of ₹54 per share.
Loading comments...